MedTrace Logo

Medication in Early Diabetes (MED) Study

NCT00437970 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2016-05-27

No results posted yet for this study

Summary

This study compares metformin (current first-line medication) to pioglitazone (a newer diabetic medication currently approved for combination use). Whilst there is good evidence for the benefits of pioglitazone use in other populations, in light of the known weight gain effects of pioglitazone we believe further assessment is required in Indigenous Australians (in whom there is a strong predisposition for central fat deposition). This study will provide evidence regarding the medication appropriate for first line medication in Type 2 diabetes in this high risk population. This study will assist clinicians to make evidenced-based decisions regarding initial medical management of those with Type 2 diabetes (where there is currently a gap in evidence).

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Pioglitazone

15mg of Pioglitazone taken orally twice a day

DRUG

Metformin

500 mg of Metformin taken orally twice a day

Sponsors & Collaborators

  • Menzies School of Health Research

    lead OTHER

Principal Investigators

  • Louise Maple Brown, MBBS PhD FRACP · Menzies School of Health Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2009-01-31
Completion
2009-02-28

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00437970 on ClinicalTrials.gov